Group 1 - Alkermes plc will participate in two upcoming investor conferences: the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 [1] - The live webcasts of the conferences will be accessible under the Investors tab on Alkermes' website and will be archived for 14 days [1] Group 2 - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience [2] - The company has a portfolio of proprietary commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - Alkermes is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2]

Group 1 - Alkermes plc will participate in two upcoming investor conferences: Stifel Healthcare Conference on November 18, 2024, at 8:35 a.m. ET and Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. ET [1] - Live webcasts of the conferences will be available under the Investors tab on Alkermes' website and will be archived for 14 days [1] Group 2 - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience [2] - The company has a portfolio of proprietary commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [2] - The company is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2]

Alkermes plc (ALKS) reported adjusted earnings from continuing operations of 73 cents per share for thirdquarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted earnings of 87 cents per share in the year-ago quarter. ALKS' total revenues of $378.1 million declined 0.7% from the year-ago quarter's level owing to lower manufacturing and royalty revenues. The top line, also, missed the Zacks Consensus Estimate of $386 million. Shares of Alkermes were down 3.6% on ...

Financial Data and Key Metrics Changes - Alkermes reported total revenues of $378.1 million for Q3 2024, reflecting an 18% year-over-year growth driven by proprietary products [10][11] - The company achieved GAAP net income from continuing operations of $92.8 million and non-GAAP net income of $121.4 million for the quarter [14] - Cash and total investments at the end of Q3 stood at $927.8 million, with approximately $116 million used for share repurchases [14] Business Line Data and Key Metrics Changes - VIVITROL net sales reached $113.7 million, a 14% increase year-over-year, with expectations for full-year sales between $410 million and $430 million [5][11] - ARISTADA product family generated net sales of $84.7 million, with expectations for full-year sales towards the lower end of the $340 million to $360 million range due to market softness [6][11] - LYBALVI net sales were $74.7 million, showing a 37% year-over-year growth, with full-year expectations between $275 million and $295 million [7][11] Market Data and Key Metrics Changes - The overall schizophrenia long-acting antipsychotic market is experiencing softness, which is expected to persist through the end of the year [6] - The company noted that approximately 55% to 57% of new patient starts for LYBALVI are coming from bipolar 1 disorder, indicating strong growth in that segment [40] Company Strategy and Development Direction - Alkermes plans to focus on driving profitability while increasing investments in growth opportunities, particularly in proprietary products and R&D initiatives [15][16] - The company aims to manage the business to deliver significant profitability and cash flow in 2025, with expectations of over $200 million in EBITDA [16][56] - Alkermes is committed to advancing the ALKS 2680 clinical program and exploring additional orexin receptor agonist candidates for future development [19][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of proprietary products and the ability to navigate competitive dynamics in the antipsychotic space [8][10] - The company is monitoring the impact of GLP-1 drugs on VIVITROL but currently does not foresee significant competition affecting its sales [25] - Management highlighted the importance of maintaining a robust cash-generating business while investing in R&D and commercial strategies [15][56] Other Important Information - Alkermes has transitioned to a financial profile driven by proprietary products and an efficient operating structure [10] - The company is actively managing its share repurchase program, with $200 million remaining from the $400 million authorization [14][61] Q&A Session Summary Question: Impact of GLP-1 drugs on VIVITROL - Management is monitoring the market but does not currently see GLP-1 drugs impacting VIVITROL sales [25] Question: Need for abuse potential studies for orexin candidates - Management confirmed that they will look at preclinical and clinical abuse potential studies for CNS active compounds [27] Question: Clarification on EBITDA guidance for 2025 - Management explained that the decrease in EBITDA guidance is primarily due to the transition away from INVEGA SUSTENNA revenue and increased R&D spending [30][31] Question: Market dynamics for LYBALVI and competition - Management noted strong growth in new patient starts for LYBALVI, particularly in bipolar 1 disorder, and does not foresee significant impact from new competitors [40][41] Question: Business development and pipeline expansion - Management expressed interest in adding non-covariate assets to the pipeline but emphasized the need for thorough due diligence [47] Question: Efficacy concerns for orexin candidates - Management indicated that the efficacy waning seen in other studies does not apply to ALKS 2680, which has shown effectiveness across a range of doses [50] Question: Future EBITDA trends and profitability - Management stated that they expect to maintain profitability while investing in growth, with plans to manage the business for sustained profitability [56][70]

Alkermes (ALKS) reported $378.14 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.7%. EPS of $0.73 for the same period compares to $0.64 a year ago.The reported revenue represents a surprise of -2.06% over the Zacks Consensus Estimate of $386.09 million. With the consensus EPS estimate being $0.78, the EPS surprise was -6.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I ...

Company Performance - Alkermes reported quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share, but showing an increase from $0.64 per share a year ago, resulting in an earnings surprise of -6.41% [1] - The company posted revenues of $378.14 million for the quarter ended September 2024, which was 2.06% below the Zacks Consensus Estimate and a decrease from $380.94 million year-over-year [1] - Over the last four quarters, Alkermes has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [1] Future Outlook - The immediate price movement of Alkermes' stock will largely depend on management's commentary during the earnings call and future earnings expectations [2] - The current consensus EPS estimate for the upcoming quarter is $0.78 on revenues of $377.63 million, while for the current fiscal year, the estimate is $2.69 on revenues of $1.51 billion [4] - The estimate revisions trend for Alkermes is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [5] - Alnylam Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.51 per share, reflecting a year-over-year change of -144.4%, with revenues anticipated to be $529.8 million, down 29.4% from the previous year [5]

Exhibit 99.1 1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2024 Financial Results — Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN, Oct. 24, 2024 — ...

— Third Quarter Revenues of $378.1 Million —— Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year —— GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 —— Company Reiterates 2024 Financial Expectations —DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024."Our third quarter financial results reflect strong year-over-year growth ...

In its upcoming report, Alkermes (ALKS) is predicted by Wall Street analysts to post quarterly earnings of $0.80 per share, reflecting an increase of 25% compared to the same period last year. Revenues are forecasted to be $388.81 million, representing a year-over-year increase of 2.1%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during t ...